Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

Journal of Clinical Oncology

Volumn 20, Issue 19, 2002, Pages 3983-3991

  Dunst, Jürgen ^a   Reese, Thomas ^a   Sutter, Thomas ^a   Zühlke, Helmut ^a   Hinke, Axel ^a   Kölling Schlebusch, Katrin ^a   Frings, Stefan ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERANCE; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CARCINOMA; SKIN TOXICITY; TOXICITY; TREATMENT OUTCOME;

EID: 0036787579     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.049     Document Type: Article

References (25)

1. Gastrointestinal Tumor Study Group: Prolongation of the diseasefree interval in surgically treated rectal carcinoma. N Engl J Med 312:465-1472, 1985
2. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
3. O'Connell MJ, Martenson JA, Weiand HS, et al: Improving adjuvant therapy by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
4. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectivity in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998
5. Schüller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
6. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
7. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001
8. Van Cutsem E, Findlay M, Osterwalder B, et al: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 18:1337-1345, 2000
9. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
10. Hoff P, Abbruzzese JL, Medgysey D, et al: A phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5-FU therapy. Proc Am Soc Clin Oncol 19:993, 2000 (abstr)
11. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
12. Twelves C, on behalf of the Xeloda Colorectal Cancer Group: Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials. Eur J Cancer 38:S15-S20, 2002
13. Judson IR, Beale PJ, Trigo JM, et al: A human capecitabine excretion balance and pharmacokinetic study after administration of a single dose of 14C-labelled drug. Invest New Drugs 17:49-56, 1999
14. Budman D, Meropol NG, Creaven P, et al: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
15. Mackean M, Planting A, Twelves C, et al: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998
16. Tepper JE, O'Connell MJ, Petroni GR, et al: Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. J Clin Oncol 15:2030-2039, 1997
17. Sawada N, Ishikawa T, Sekiguchi F, et al: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5:2948-2953, 1999
18. Piantadosi S: Clinical Trials: A Methodologic Perspective. New York, NY, John Wiley, 1997, pp 151-155
19. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
20. Rödel C, Hohenberger W, Sauer R: Adjuvant and neoadjuvant therapy of rectal carcinoma: The current status. Strahlenther Onkol 175:133, 1999
21. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
22. Byfield JE, Calabro-Jones P, Klisak I, et al: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 8:1923-1933, 1982
23. Byfield JE, Sharp TR, Frankel SS, et al: Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 2:406-413, 1984
24. Rödel C, Fietkau R, Keilholz L, et al: The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma. Strahlenther Onkol 173:415-421, 1997
25. Yoon W, Choi J, Kim T, et al: Enhanced tumor response and sphincter preservation with preoperative chemoradiation (CXRT) using capecitabine for locally advanced rectal cancer. Eur J Cancer 37:S258, 2001 (suppl 6, abstr)